B
Brian Skinnider
Researcher at University of British Columbia
Publications - 50
Citations - 2317
Brian Skinnider is an academic researcher from University of British Columbia. The author has contributed to research in topics: Lymphoma & ABVD. The author has an hindex of 20, co-authored 43 publications receiving 2070 citations. Previous affiliations of Brian Skinnider include BC Cancer Agency & Vancouver General Hospital.
Papers
More filters
Journal ArticleDOI
Outcomes in splenic marginal zone lymphoma: analysis of 107 patients treated in British Columbia
Katharine H. Xing,Amrit Kahlon,Brian Skinnider,Joseph M. Connors,Randy D. Gascoyne,Laurie H. Sehn,Kerry J. Savage,Graham W. Slack,Tamara Shenkier,Richard Klasa,Alina S. Gerrie,Diego Villa +11 more
TL;DR: It is shown that splenectomy remains a reasonable treatment for patients with SMZL and the 10‐year transformation rate was 18%.
Journal ArticleDOI
Bone marrow involvement in T-cell-rich B-cell lymphoma.
TL;DR: The histologic and immunohistochemical findings in specimens from bone marrow (BM) biopsies performed for staging purposes in 13 patients with a previous tissue-based diagnosis of T-cell-rich B-cell lymphoma are described and the possible relationship to these two entities is discussed.
Journal ArticleDOI
Long-term results of PET-guided radiation in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP.
Ciara L. Freeman,Kerry J. Savage,Diego Villa,David W. Scott,Line Srour,Alina S. Gerrie,Maura J. Brown,Graham W. Slack,Pedro Farinha,Brian Skinnider,James Morris,Francois Benard,Christina Aquino-Parsons,Andrea Lo,Tom Pickles,Don Wilson,Petter Tonseth,Joseph M. Connors,Laurie H. Sehn +18 more
TL;DR: Data suggest that patients with advanced-stage DLBCL that are PET-NEG at EOT and receive no RT have excellent outcomes, and FDG-PET can reliably guide selective administration of consolidative RT, even for patients with initially bulky disease.
Journal ArticleDOI
Outcome of primary mediastinal large B-cell lymphoma using R-CHOP: impact of a PET-adapted approach.
Anna Hayden,Petter Tonseth,Derrick G. Lee,Diego Villa,Alina S. Gerrie,David Scott,Ciara L. Freeman,Graham W. Slack,Pedro Farinha,Brian Skinnider,Paul R. Yenson,Francois Benard,Andrea Lo,Tom Pickles,Donald A. Wilson,Joseph M. Connors,Laurie H. Sehn,Kerry J. Savage +17 more
TL;DR: Outcomes for PMBCL patients treated with R-CHOP are favorable and use of a PET-adapted approach reduces RT in the majority of patients, and a small proportion have refractory disease and may benefit from an alternate treatment.
Journal ArticleDOI
Anaplastic large cell lymphoma: a clinicopathologic analysis.
TL;DR: In this article, the authors reviewed the clinicopathologic features of ALCL using a combination of clinical, phenotypic, and genotypic features, and identified several distinct clinical entities.